Brand Name: Provenge®
Sipuleucel-T is used in the treatment of advanced prostate cancer.
Sipuleucel-T is a type of immunotherapy. It is prepared using cells from a patient’s own blood, and so is called autologous (self) cellular immunotherapy. Sipuleucel-T works by triggering the body’s natural immune system to fight cancer cells.
This medication is given as an injection into a vein (intravenous). Each injection usually takes about 60 minutes, and is typically given once every 2 weeks for about 6 weeks (three doses total). Using a procedure called “leukapheresis,” white blood cells are removed from the body about 3 days before the injection is given. The white blood cells are combined with a protein and then injected together. Each preparation of sipuleucel-T is specific for each patient.
Sipuleucel-T side effects
To prevent problematic interactions between sipuleucel-T and other drugs, be sure to tell your doctor if you are allergic to any medications, and what other medications and supplements you are currently taking. You should also inform your doctor if you have or ever had a stroke, lung disease, high blood pressure, liver tumor, liver disease, or kidney disease. Sipuleucel-T is for use in men only.
Possible side effects of sipuleucel-T may include:
- Tiredness or weakness
- Joint pain
- Muscle pain or tightening
- Uncontrollable shaking of a part of the body
Some of sipuleucel-T’s side effects can be serious. Call your doctor immediately if you experience any of these symptoms:
- Redness or swelling near the site of injection or cell removal
- Fever over 100.4°F
- Slow or difficult speech
- Sudden dizziness or faintness
- Difficulty swallowing
- Blood in urine
Please note that this is not a comprehensive list. Patients may experience additional effects not mentioned above.
At Cancer Treatment Centers of America (CTCA), your team of cancer experts will explain each of the side effects of sipuleucel-T with you in detail, as well as the side effects and expectations of all other medications planned as part of your individualized treatment plan.
Sipuleucel-T for cancer treatment
Sipuleucel-T is approved by the FDA for the following:
- Treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer
At Cancer Treatment Centers of America (CTCA), our integrative approach to cancer treatment works to fight your disease on all fronts and ensures that you remain at the center of everything we do. We encourage participation from both you and your family to make certain you are comfortable with all decisions made regarding your treatment